---
schema_version: "secwatch.filing_event.v1"
accession: "0001723128-25-000059"
form_type: "8-K"
ticker: "AMRX"
cik: "0001723128"
company_name: "Amneal Pharmaceuticals, Inc."
filed_at: "2025-10-30T23:59:59+00:00"
generated_at: "2026-05-17T01:23:05.336853+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amneal Q3 revenue $785M (+12% YoY); GAAP EPS $0.01, adj. EPS $0.17; updated FY guidance

## Summary
- Net revenue $785M (+12% YoY); GAAP net income $2M vs loss of $0.2M; diluted EPS $0.01.
- Adjusted EBITDA $160M (+1% YoY); adjusted diluted EPS $0.17 (+6% YoY from $0.16).
- Specialty +8% driven by CREXONT and UNITHROID; Affordable Medicines +8%; AvKARE +24%.
- Incurred $22.5M milestone for XOLAIR biosimilar BLA submission; updated FY2025 guidance.
- Launched BREKIYA autoinjector for migraine in October 2025.

## SEC filing metadata
- accession: 0001723128-25-000059
- form_type: 8-K
- ticker: AMRX
- cik: 0001723128
- company_name: Amneal Pharmaceuticals, Inc.
- filed_at: 2025-10-30T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000059/0001723128-25-000059-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1723128/000172312825000059/amrx-20251030.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001723128-25-000059
- JSON: https://secwatch.observer/filing/0001723128-25-000059.json
- Plain text: https://secwatch.observer/filing/0001723128-25-000059.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.